Quantcast

Latest Spasmodic torticollis Stories

2011-03-30 07:11:00

GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for Xeomin® (incobotulinumtoxinA). Merz expects that this unique billing code, which will become effective on April 1, 2011, will help simplify the billing and reimbursement process for prescribers of XEOMIN. The U.S. Food and Drug...

2011-03-09 13:01:34

Implanting electrodes into a pea-sized part of the brain can dramatically improve life for people with severe cervical dystonia "“ a rare but extremely debilitating condition that causes painful, twisting neck muscle spasms "“ according to the results of a pilot study led by Jill Ostrem, MD and Philip Starr, MD PhD at the University of California, San Francisco. Today, people with cervical dystonia can be treated with medications or injections of botulinum toxin (e.g.,...

2011-03-08 07:11:00

GREENSBORO, N.C., March 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum toxin type A free from accessory proteins that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum...

2011-02-02 07:11:00

GREENSBORO, N.C., Feb. 2, 2011 /PRNewswire/ -- In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias (movement disorders characterized by muscle contractions and spasms that cause twisting and...

2011-01-18 14:59:52

Michele Tagliati, M.D., new director of Cedars-Sinai's Movement Disorders Program, says certain disabilities "remain remarkably stable" long-term in treated patients Parkinson's disease symptoms begin subtly and worsen as damage to certain brain cells continues. But an electrical stimulation device implanted deep in the brain and programmed remotely, along with medications, may provide some control of "motor symptoms" common to the disease, such as shaking, stiffness, and loss of muscle...

2010-12-02 21:34:47

Botulinum toxin A creates muscle weakness and atrophy following long term use A new study by researchers at the Faculty of Kinesiology, University of Calgary, is raising questions about the therapeutic use of botulinum toxin A. The study found that animals injected with Clostridium Botulinum type A neurotoxin complex (BOTOX, Allergan, Inc., Toronto, Ontario, Canada) experienced muscle weakness in muscles throughout the body, even though they were far removed from the injection site. The study...

2010-11-05 07:11:00

GREENSBORO, N.C., Nov. 5, 2010 /PRNewswire/ -- Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash. The U.S. Food and Drug Administration (FDA) approved XEOMIN on July 30, 2010, for the treatment of...

2010-10-05 07:11:00

GREENSBORO, N.C., Oct. 5 /PRNewswire/ -- Merz Pharmaceuticals today announced that Xeomin® (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010. XEOMIN is a botulinum toxin type A that is free from accessory proteins. It is FDA-approved for the treatment of adults with...

2010-08-02 07:11:00

GREENSBORO, N.C., Aug. 2 /PRNewswire/ -- Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people...

2010-04-21 07:00:00

PHOENIX, April 21 /PRNewswire/ -- One of the world's most fashionable beauty treatments is gaining popularity for something other than the war on wrinkles. Botulinum Toxin, commonly known as Botox, is being used at the Muhammad Ali Parkinson Center at Barrow Neurological Institute to help manage symptoms associated with Parkinson's disease and other movement disorders. "Botox is the most powerful nerve toxin known to man and it's dramatically improving the quality of life for people with...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related